本研究旨在评估口服 azacitidine 于香港确诊急性髓系白血病（AML）成人患者的真实世界疗效及安全性。
适应症：Acute Myeloid Leukemia (AML)
入组条件
纳入标准
- Documented diagnosis of Acute Myeloid Leukemia (AML).
- Achieved first complete response (CR) or complete response with incomplete blood recovery (CRi) following intensive induction chemotherapy.
- Not able or unwilling to undergo Hematopoietic Stem Cell Transplantation (HSCT).
- Received oral azacitidine as maintenance therapy after first CR or CRi following intensive induction chemotherapy in real-world settings (Note: CR/CRi status at oral azacitidine treatment initiation is left to the judgment of the local clinicians depending on the treatment response and the condition of the patient in routine clinical practices).
- Age ≥ 18 years at the index date (oral azacitidine initiation date).
排除标准
- Evidence of relapse prior to oral azacitidine initiation recorded in electronic health record (EHR).
入组条件维持 ClinicalTrials.gov 原始英文登记资料，实际入组资格以研究团队的正式评估与受试者知情同意书为准。资料来源：ClinicalTrials.gov，每两周自动更新，最后同步：2026年10月8日。